Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

The skin cancer vaccine is based on mRNA technology that helped end the coronavirus pandemic.

Last fall, FDA safety officers began compiling a list of children possibly killed by COVID vaccines. Digging through ...

The data were not bad — in fact, the outcome was better than many analysts had predicted. The problem was Cambridge-based ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

So, right now, is Moderna a buy on the dip? It's important to keep in mind that the stock still has climbed more than 500% ...

Moderna (NASDAQ: MRNA) leaped into the spotlight during the early days of the pandemic, and that was because the up-and-coming biotech player had a solution to the problem: a vacc ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were ...

Moderna aur Merck ke shares gire jab vaccine trial data ne sirf **42%** recurrence reduction dikhaya. Investors ki badhi ...

A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.